Meeting
2020 ASCO Virtual Scientific Program
Phase II study of pembrolizumab plus olaparib in the treatment of patients with advanced cholangiocarcinoma.
Authors
Aiwu Ruth He
Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC
Aiwu Ruth He , Benjamin Adam Weinberg , Marcus Smith Noel , Violeta P Milic , Petra Prins , Hongkun Wang , Marion L. Hartley , John Marshall
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
pending at time of submission
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS4659)
DOI
10.1200/JCO.2020.38.15_suppl.TPS4659
Abstract #
TPS4659
Poster Bd #
267
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase II study of combination pembrolizumab and olaparib in patients with advanced cholangiocarcinoma: Interim results.
First Author: Chao Yin
Poster
2019 ASCO Annual Meeting
Dora: A randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum responsive advanced triple-negative breast cancer (aTNBC).
First Author: Sarah Sammons
First Author: Igor Tsaur